Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C
✍ Scribed by Y. Rodríguez-Muñoz; S. Martín-Vílchez; R. López-Rodríguez; Á. Hernández-Bartolomé; M. Trapero-Marugán; M. J. Borque; R. Moreno-Otero; P. Sanz-Cameno
- Book ID
- 108606426
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 447 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0269-2813
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Peripheral blood mononuclear cell proliferative responses in uitro to recombinant yeast or Escherichia coli hepatitis C virus fusion proteins were evaluated in 20 patients with chronic hepatitis C who were reactive for antibody to hepatitis C virus (on enzyme immunoassay, version 2.0, and a four-ant
In previous studies employing interferons (IFNs) in the treatment of chronic hepatitis C, there have been few reliable predictors of sustained responses. We retrospectively evaluated the predictive value of hepatitis C virus (HCV)-RNA measurements in the first few months during consensus interferon
Hepatitis C virus (HCV) can infect peripheral blood mately 10 kb. 2 Acute posttransfusion hepatitis C mononuclear cells (PBMC) of patients with chronic HCV (PTHC) is followed by chronic hepatitis in about 50% infection. No data are available on PBMC testing for of the cases. Chronic hepatitis may al
Only half of patients with chronic hepatitis C virus (HCV) infection and genotype-1 show a sustained antiviral response to the current antiviral therapy. The reason this treatment fails is unclear, and no reliable marker exists that predicts the treatment outcome. In the present study, we investigat
The response to antiviral therapy for chronic hepatitis C virus (HCV) is complex and is determined by both environmental and genetic factors. Recently, interacting gene polymorphisms of the chemokine RANTES have been shown to affect HIV disease progression. Our aim was to assess if these RANTES vari